Pharming Group NV is raising more than €25 million and converting €5.8 million of debt to equity. The Dutch biotechnology firm, which has struggled financially and emerged from court protection in October 2002, plans to use proceeds for general corporate purposes and to continue development of its lead product, a recombinant form of human C1 inhibitor (rhC1INH). (BioWorld International)
Pharming Group NV is raising more than €25 million and converting €5.8 million of debt to equity. The Dutch biotechnology firm, which has struggled financially and emerged from court protection in October 2002, plans to use proceeds for general corporate purposes and to continue development of its lead product, a recombinant form of human C1 inhibitor (rhC1INH). (BioWorld International)
Elan Corp. plc aims to launch its non-opioid peptide-based analgesic Prialt "no later" than the first quarter of 2005, following news that the compound met its primary endpoint in a trial of 220 patients with severe chronic pain who had not obtained relief with other therapies. (BioWorld International)
Elan Corp. plc aims to launch its non-opioid peptide-based analgesic Prialt "no later" than the first quarter of 2005, following news that the compound met its primary endpoint in a trial of 220 patients with severe chronic pain who had not obtained relief with other therapies. (BioWorld International)
